Submitted on February 7, 2017 - USP Comment Letter to FDA on the FDA's issuance of the List of Bulk Drug Substances that Can Be Used To Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act. Docket Number FDA-2016-N-3464.
-
Diversity, equity, inclusion and belonging at USPUSP aspires to be a diverse, inclusive, innovative, and engaging organization that empowers and engages staff and volunteers.
History of USPUSP has been building trust in medicine for over 200 years.
-
Promoting the Quality of Medicines Plus (PQM+) annual reportThe goal of the PQM+ Program is to sustainably strengthen medical product quality assurance systems in low and middle-income countries.
APEC Supply Chain Security ToolkitThe Toolkit is a resource that addresses areas of vulnerability in the medical product supply chain through prevention, detection, and response strategies and actions.
Complex GenericsAddressing barriers to the development of complex generics: Understanding challenges and opportunities.